The primary efficacy outcome occurred in 22/299 ( 7.4 % ) and 41/295 ( 13.9 % ) patients in the edoxaban and enoxaparin groups , respectively ( relative risk reduction = 46.8 % ) , indicating non-inferiority ( P < 0.001 ) and superiority ( P = 0.010 ) of edoxaban versus enoxaparin .